
ALT 🧠 **An Alzheimer’s drug is clearing brain plaques and allowing some patients to stop treatment within a year.** Scientists are studying a remarkable possibility with a drug called donanemab. This antibody medicine targets amyloid, a sticky protein that builds up into plaques in the brains of people with Alzheimer’s disease. In a major clinical trial involving more than 1,700 people with early Alzheimer’s, donanemab slowed the decline in memory and thinking by up to 35% compared with a placebo in certain groups. But the most surprising part came afterward. Brain scans showed that some patients had cleared enough amyloid plaque to stop treatment. Nearly half of those receiving the drug were able to stop within 12 months under the trial's treatment rules.















